Bortezomib: Proteasome inhibition as an effective anticancer therapy

Annual Review of Medicine

Volumn 57, Issue , 2006, Pages 33-47

  Richardson, Paul G ^a   Mitsiades, Constantine ^a   Hideshima, Teru ^a   Anderson, Kenneth C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Lymphoma; Multiple myeloma; Nuclear factor B

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IRINOTECAN; LENALIDOMIDE; MELPHALAN; OBLIMERSEN; PROTEASOME INHIBITOR; THALIDOMIDE;

ANEMIA; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CARCINOMA; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; FATIGUE; FLUID RETENTION; HAND FOOT SYNDROME; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOKALEMIA; HYPONATREMIA; KIDNEY CARCINOMA; LIMB PAIN; LIVER CELL CARCINOMA; LUNG CARCINOMA; LYMPHOCYTOPENIA; MALAISE; META ANALYSIS; MULTIPLE MYELOMA; MYELOMA; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; ORTHOSTATIC HYPOTENSION; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; SIDE EFFECT; SOLID TUMOR; SYNCOPE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; WEAKNESS;

BORONIC ACIDS; CLINICAL TRIALS; HUMANS; NEOPLASMS; PROTEASE INHIBITORS; PYRAZINES;

EID: 32944469894     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.57.042905.122625     Document Type: Review

References (57)

1. Hideshima T, Richardson P, Chauhan D, et al. 2001. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61(7):3071-76
2. Hideshima T, Chauhan D, Richardson P, et al. 2002. NF-kappa B as a therapeutic target in multiple myeloma. J. Biol. Chem. 277(19):16639-47
3. Hideshima T, Chauhan D, Hayashi T, et al. 2003. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 22(52):8386-93
4. Hideshima T, Mitsiades C, Akiyama M, et al. 2003. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101(4):1530-34
5. Mitsiades N, Mitsiades CS, Poulaki V, et al. 2002. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl. Acad. Sci. USA 99(22):14374-79
6. Mitsiades N, Mitsiades CS, Richardson PG, et al. 2003. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101(6):2377-80
7. Aghajanian C, Soignet S, Dizon DS, et al. 2002. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. 8(8):2505-11
8. Jagannath S, Barlogie B, Berenson J, et al. 2004. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br. J. Haematol. 127(2):165-72
9. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. 2002. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 20(22):4420-27
10. Richardson PG, Barlogie B, Berenson J, et al. 2003. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348(26):2609-17
11. Adams J, Palombella VJ, Sausville EA, et al. 1999. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59(11):2615-22
12. Ling YH, Liebes L, Jiang JD, et al. 2003. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin. Cancer Res. 9(3):1145-54
13. Pham LV, Tamayo AT, Yoshimura LC, et al. 2003. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J. Immunol. 171(1):88-95
14. Teicher BA, Ara G, Herbst R, et al. 1999. The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. 5(9):2638-45
15. Cusack JC Jr., Liu R, Houston M, et al. 2001. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 61(9):3535-40
16. Ma MH, Yang HH, Parker K, et al. 2003. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin. Cancer Res. 9(3):1136-44
17. Jemal A, Tiwari RC, Murray T, et al. 2004. Cancer statistics, 2004. CA Cancer J. Clin. 54(1):8-29
18. Attal M, Harousseau JL, Facon T, et al. 2003. Single versus double autologous stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 349(26):2495-2502
19. Child JA, Morgan GJ, Davies FE, et al. 2003. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Engl. J. Med. 348(19):1875-83
20. Segeren CM, Sonneveld P, van der HB, et al. 2003. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 101(6):2144-51
21. Kumar SK, Therneau TM, Gertz MA, et al. 2004. Clinical course of patients with relapsed multiple myeloma. Mayo Clin. Proc. 79(7):867-74
22. Attal M, Harousseau J-L, Stoppa A-M, et al. 1996. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N. Engl. J. Med. 335(2):91-97
23. Greipp PR, Lust JA, O'Fallon WM, et al. 1993. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 81(12):3382-87
24. 23a. International Myeloma Foundation. The myeloma matrix part I (phase II → FDA approved). http://66.223.50.155/main. jsp?type=article&id=735. Accessed July 12, 2005
25. Papandreou CN, Daliani DD, Nix D, et al. 2004. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J. Clin. Oncol. 22(11):2108-21
26. Jagannath S, Barlogie B, Berenson JR, et al. 2005. Bortezomib in relapsed and/or refractory multiple myeloma: initial clinical experience in patients with impaired renal function. Cancer 103(6):1195-2000
27. Nix D, Ryan DP, Eder JP, et al. 2003. Pharmacokinetics of gemcitabine and the proteasome inhibitor bortezomib (formerly PS-341) in adult patients with solid malignancies. Proc. Am. Assoc. Cancer. Res. 44(2):1061
28. Supko JG, Eder JP, Lynch TJ, et al. 2003. Pharmacokinetics of irinotecan and the proteasome inhibitor bortezomib in adult patients with solid malignancies. Proc. Am. Soc. Clin. Oncol. 22:136
29. VELCADE® (bortezomib) for injection. http://www.millennium.com/ products/vel cade/index.asp. Accessed July 12, 2005
30. National Institutes of Health. Bortezomib in treating patients with advanced cancer and kidney dysfunction. http://clinicaltria ls.gov(ct/gui/show/ NCT00054483?order =3. Accessed July 12, 2005
31. National Institutes of Health. Bortezomib in treating patients with advanced cancer and liver dysfunction. http://clinicaltrials. gov/ct/gui/show/NCT00091117?order=1. Accessed July 12, 2005
32. Cortes J, Thomas D, Koller C, et al. 2004. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin. Cancer Res. 10(10):3371-76
33. Berenson J, Yang H, Swift R, et al. 2005. Bortezomib in combination with melphalan in the treatment of relapsed or refractory multiple myeloma: a phase I/II study. Haematologica 90(Suppl. 1):150-51
34. Orlowski R, Voorhees P, Garcia R, et al. 2005. Phase I study of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105(8):3058-65
35. Richardson PG, Barlogie B, Berenson J, et al. 2004. Survival, duration of response, and time to progression with bortezomib in patients with relapsed and refractory myeloma: an update of the SUMMIT trial with additional follow-up. Hematol. J. 5(Suppl. 2):S103-4
36. Bladé J, Samson D, Reece D, et al. 1998. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br. J. Haematol. 102(5):1115-23
37. Jagannath S, Richardson P, Barlogie B, et al. 2004. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma. Hematol. J. 5(Suppl. 2):S130
38. Oakervee HE, Popat R, Curry N, et al. 2005. PAD combination therapy (bortezomib, formerly PS-341, Adriamycin and dexamethasone) for previously untreated patients with multiple myeloma. Br. J. Haematol. 129(6):755-62
39. Jagannath S, Durie B, Wolf J, et al. 2005. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br. J. Haematol. 129(6):776-83
40. Goy A, Younes P, McLaughlin P, et al. 2005. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 23(4):667-75
41. O'Connor OA, Wright J, Moskowitz CH, et al. 2005. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J. Clin. Oncol. 23(4):676-84
42. Assouline S, Belch A, Sehn L, et al. 2003. A phase II study of bortezomib in patients with mantle cell lymphoma. Blood 102:902a (Abstr.)
43. Kondagunta GV, Drucker B, Schwartz L, et al. 2004. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J. Clin. Oncol. 22(18):3720-25
44. Davis NB, Taber DA, Ansari RH, et al. 2004. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J. Clin. Oncol. 22(1):115-19
45. Dragovich T, Lenz HJ, Rocha Lima CMS, et al. 2004. Bortezomib ± irinotecan in relapsed/refractory colorectal cancer (CRC): interim analysis results from a phase (ph) 2b study. J. Clin. Oncol. 22(Suppl. 14):267s
46. Fanucchi MP, Belt RJ, Fossella FV, et al. 2004. Phase (ph) 2 study of bortezomib ± docetaxel in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC). Preliminary results. J. Clin. Oncol. 22(Suppl. 14):643s
47. Stevenson J, Nho CW, Johnson SW, et al. 2004. Phase II/pharmacodynamic trial of PS-341 (bortezomib, VELCADE®) in advanced non-small cell lung cancer. J. Clin. Oncol. 22(Suppl. 14):652s
48. Dreicer R, Roth B, Petrylak D, et al. 2004. Phase I/II trial of VELCADE® plus docetaxel in patients with advanced androgen-independent prostate cancer. J. Clin. Oncol. 22(Suppl. 14):420s
49. Shah MH, Young D, Kindler HL, et al. 2004. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin. Cancer Res. 10(18, Pt. 1):6111-18
50. Hegewisch-Becker S, Sterneck M, Schubert U, et al. 2004. Phase I/II trial of bortezomib (VELCADE®) in patients with unresectable hepatocellular carcinoma. J. Clin. Oncol. 22(Suppl. 14):335s
51. Richardson P, Sonneveld P, Schuster MW, et al. 2005. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352(24):2487-98
52. 47a. U.S. Food and Drug Administration, http: //www.fda.gov/medwatch/ SAFETY/2004 /may04.htm. Accessed July 12, 2005
53. Berenson JR, Jagannath S, Barlogie B, et al. 2005. Safety of prolonged therapy with bortezomib in relapsed/refractory multiple myeloma. Cancer. In press
54. Lonial L, Waller EK, Richardson PG, et al. 2004. Evaluation of the severity and risk of thrombocytopenia with bortezomib therapy in relapsed and refractory multiple myeloma. Hematol. J. 5(Suppl. 2):S130-31
55. Goldberg AL. 2003. Protein degradation and protection against misfolded or damaged proteins. Nature 426(6968):895-99
56. Adams J. 2004. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5(5):417-21
57. Adams J. 2004. The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer 4(5):349-60